Table 2.
Clinical Characteristics and Inflammatory Parameters Among the Different Psoriasis Groups [Mean ± SD, M(IQR)]
| Parameter | Healthy groups | PV | PA | EP | GPP | F/H | P |
|---|---|---|---|---|---|---|---|
| N | 40 | 17 | 18 | 5 | 5 | - | - |
| Age (year) | 36.000 ± 8.659 | 37.059 ± 9.202 | 35.278 ± 9.809 | 42.200 ± 8.408 | 43.800 ± 9.039 | 1.406 | 0.240 |
| Men (%) | 47.500 | 52.941 | 55.556 | 60.000 | 40.000 | 0.773 | 0.942 |
| Duration (year) | 0.000 (0.000)* | 6.147 ± 0.803* | 5.000 (8.500)* | 11.200 ± 1.985* | 7.000 ± 2.168* | 71.581 | < 0.001 |
| PASI | 0.000 (0.000)* | 18.171 ± 1.490* | 14.250 (9.550)* | 42.700 ± 2.337* | 20.620 ± 3.896* | 74.417 | < 0.001 |
| Leukocytes (× 109/L) | 6.798 ± 2.064* | 6.871 ± 1.671* | 6.806 ± 1.435* | 17.792 ± 4.086* | 10.536 ± 1.926* | 37.147 | < 0.001 |
| Neutrophil (× 109/L) | 4.566 ± 1.951* | 4.634 ± 1.397* | 4.679 ± 1.451* | 14.874 ± 3.985* | 8.398 ± 1.551* | 37.473 | < 0.001 |
| Lymphocytes (× 109/L) | 1.946 ± 0.520 | 1.971 ± 0.704 | 1.965 (0.350) | 2.004 ± 0.615 | 1.988 ± 0.518 | 0.212 | 0.995 |
| Platelets (× 109/L) | 235 ± 60* | 239 (64)* | 263 ± 101* | 460 ± 100* | 316 ± 83 | 15.410 | 0.004 |
| ESR (mm/h) | 12 (6)* | 19 ± 11* | 44 ± 34* | 118 ± 48* | 82 ± 23* | 38.109 | < 0.001 |
| CRP (mg/L) | 5.740 (5.530)* | 8.330 (11.135)* | 16.945 (40.160)* | 73.484 ± 9.991* | 65.334 ± 58.328* | 42.070 | < 0.001 |
| NLR | 2.105 (1.416)* | 3.306 ± 0.815* | 3.292 ± 0.734* | 9.180 ± 2.262* | 5.196 ± 0.925* | 36.933 | < 0.001 |
| PLR | 127.941 ± 43.173* | 139.940 (70.320)* | 146.414 ± 75.668* | 240.004 ± 62.587* | 162.852 ± 41.455 | 12.680 | 0.013 |
NLR neutrophil-to-lymphocyte ratio, PASI Psoriasis Area and Severity Index, PLR platelet-to-lymphocyte ratio
*P < 0.05